Evaluation of tissue and circulating mir-21 as potential biomarker of response to chemoradiotherapy in rectal cancer

Susana Ourô, Cláudia Mourato, Marisa P. Ferreira, Diogo Albergaria, André Cardador, Rui E. Castro, Rui Maio, Cecília M.P. Rodrigues

Research output: Contribution to journalArticle

Abstract

Response to chemoradiotherapy (CRT) in patients with locally advanced rectal cancer (RC) is quite variable and it is urgent to find predictive biomarkers of response. We investigated miR-21 as tissue and plasma biomarker of response to CRT in a prospective cohort of RC patients; The expression of miR-21 was analyzed in pre-and post-CRT rectal tissue and plasma in 37 patients with RC. Two groups were defined: Pathological responders (TRG 0, 1 and 2) and non-responders (TRG 3). The association between miR-21, clinical and oncological outcomes was assessed; miR-21 was upregulated in tumor tissue and we found increased odds of overexpression in pre-CRT tumor tissue (OR: 1.63; 95% CI: 0.40–6.63, p = 0.498) and pre-CRT plasma (OR: 1.79; 95% CI: 0.45–7.19, p = 0.414) of non-responders. The overall recurrence risk increased with miR-21 overexpression in pre-CRT tumor tissue (HR: 2.175, p = 0.37); Significantly higher miR-21 expression is observed in tumor tissue comparing with non-neoplastic. Increased odds of non-response is reported in patients expressing higher miR-21, although without statistical significance. This is one of the first studies on circulating miR-21 as a potential biomarker of response to CRT in RC patients.

Original languageEnglish
Article number246
JournalPharmaceuticals
Volume13
Issue number9
DOIs
Publication statusPublished - Sep 2020

Keywords

  • Biomarkers
  • Chemoradiotherapy
  • MiR-21
  • Rectal cancer
  • Therapy response
  • Tumor regression grade

Fingerprint Dive into the research topics of 'Evaluation of tissue and circulating mir-21 as potential biomarker of response to chemoradiotherapy in rectal cancer'. Together they form a unique fingerprint.

Cite this